Adverse events associated with mefloquineBMJ 1996; 313 doi: https://doi.org/10.1136/bmj.313.7071.1552b (Published 14 December 1996) Cite this as: BMJ 1996;313:1552
Study in returned travellers confirms authors' findings
- E L Corbett,
- J F Doherty,
- R H Behrens
- Registrar in tropical medicine Senior registrar in tropical medicine Consultant physician in travel medicine Hospital for Tropical Diseases, London NW1 0PE
EDITOR,—The excess of disabling neuropsychiatric side effects of mefloquine reported by P J Barrett and colleagues has attracted attention.1 Focus on disabling reactions has detracted from milder disturbances, which may be sufficiently common to reduce compliance and increase the risk of malaria.2 We conducted a questionnaire based survey among recently returned travellers to assess the impact of adverse reactions on compliance.
Altogether 347 questionnaires were returned (response rate 60.5%), 255 of which were from respondents who had been born in malaria free areas, were …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial